TABLE 2.

Hepatitis C Virus Pediatric Antiviral Treatment

Patients Undergoing Treatment (n = 29)—Therapy
	n°	%	Weeks
DAAs therapy
Sofosbuvir/Ledipasvir	13	45	12 (n = 13)
Ombitasvir/paritaprevir/ritonavir + dasabuvir	4	14	12 (n = 4)
Glecaprevir/pibrentasvir	8	28	8 (n = 7), 12 (n = 1)
Sofosbuvir + Ribavirin	2	7	12 (n = 1), 24 (n = 1)
Sofosbuvir/Velpatasvir/Voxilaprevir	1	3	8 (n = 1)
No DAA
Interferon + Ribavirin	1	3	24 (n = 1)

Description of antiviral treatment received by HCV pediatric patients: DAA, direct-acting antiviral agents; Weeks of treatment: in the brackets is specified the number of patients who completed the weeks of treatment.